In conclusion, the interim results of this study show that 68Ga-PSMA-PET screening prior to SRT to the prostate bed alone fails to detect metastatic disease in the majority of patients who subsequently relapse. This evidence concerns the gene FOLH1 and metastatic neoplasm.